Capricor Therapeutics, Inc.
Undisclosed program
Duchenne muscular dystrophy
Resolved
98days ago
Phase 3 readout · ~ Mar 31, 2026 estimated
What's at stake
Phase 3 trial results for Undisclosed program in Duchenne muscular dystrophy are due ~ Mar 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpoints.”